Frontier IP Group plc New Portfolio Company - Tarsis Technology Limited
December 07 2016 - 2:00AM
RNS Non-Regulatory
TIDMFIPP
Frontier IP Group plc
07 December 2016
RNS REACH
AIM: FIPP
7 December 2016
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - Tarsis Technology Limited
Frontier IP, which specialises in the commercialisation of
intellectual property, is pleased to announce that it has received
a 20 per cent. stake in Tarsis Technology Limited ("Tarsis"), the
Group's third spin-out from the Department of Chemical Engineering
and Biotechnology at the University of Cambridge.
Tarsis plans to develop and commercialise technology created by
Dr. David Fairen-Jimenez, a Royal Society University Research
Fellow at the Department of Chemical Engineering and Biotechnology
at the University of Cambridge, and his research team. The
technology allows slower and more controlled delivery of drugs
using metal-organic frameworks (MOFs). The pharmaceutical industry
has demonstrated early interest in the technology.
Frontier IP's role will be to provide commercialisation services
and in-depth pharmaceutical industry expertise. Dr. Campbell
Wilson, a non-executive director of Frontier IP, has been appointed
as a non-executive director of Tarsis. Dr. Wilson is currently a
member (and past chairman) of the Board of the UK Pharmaceutical
Licensing Group and has worked in the pharmaceutical industry for
over 35 years.
Dr. Campbell Wilson, Non- Executive Director of Frontier IP and
Director of Tarsis, said:
"We are looking forward to working with Dr. Fairen-Jimenez on
this promising opportunity. Frontier IP brings experience in
commercialising IP and relationships with key players in relevant
markets. Dr. Fairen-Jimenez's technology approach combined with our
support and network in the pharmaceutical space can help accelerate
the commercialisation for this exciting technology."
Dr. David Fairen-Jimenez, Chief Executive of Tarsis, said:
"This is a great opportunity to see the state-of-the-art
materials we prepare in our labs move into the market. The synergy
between Frontier IP and their experience in new ventures and in the
pharmaceutical industry combined with our leading work in advanced
materials for drug delivery will give a strong commercial dimension
to this project."
ENDS
Enquiries
Frontier IP Group Plc T: 0131 240 1251
Neil Crabb, Chief Executive
Cantor Fitzgerald Europe T: 020 7894 7000
(Nominated Adviser and Joint
Broker)
David Foreman, Catherine
Leftley, Corporate Finance
David Banks, Sales
Peterhouse Corporate Finance T: 020 7469 0935
Limited
(Joint Broker)
Lucy Williams
Kreab T: 020 7074 1800
(Financial PR)
Robert Speed, Matthew Jervois
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies
in the commercialisation and exploitation of their intellectual
property. It establishes formal and informal relationships with
sources of exploitable IP, principally universities. Its core
business is building and growing a portfolio of equity stakes in
spin-out companies by taking an active involvement in the
commercialisation and funding of these businesses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLBDDSUGBGLL
(END) Dow Jones Newswires
December 07, 2016 02:00 ET (07:00 GMT)